Description
A Novel Myeloprotection Therapy
In this presentation, Ms. Bukolt will:
Review the burden and current treatment landscape of chemotherapy-induced myelosuppression
Introduce the mechanism of action and key efficacy and safety data of the first and only proactive multilineage myeloprotection therapy for patients with extensive-stage small cell lung cancer
Explore adverse reactions, dosing and administration and the G1 to One™ patient support program
Speaker(s):
